Chemotherapy, Antibiotics, and Gene Therapy JPET #160044
Introduction
The treatment of malignant brain tumors presents continuing challenges. Conventional therapy by surgical debulking and followed by radiation and chemotherapy generally is not curative. Chemotherapy fails for pathophysiological, pharmacological, and pharmaceutical reasons. Poor perfusion, tortuous and poorly-permeable vasculature, and drug resistance are tumor properties that hinder drug penetration, deposition, and retention (Tredan et al., 2007) .
Sub-optimal drug properties, including poor intrinsic membrane-and tissue permeability, short circulating half-life, and rapid metabolism also impede therapy.
Incorporation of drugs in particulate carriers such as emulsions, nanoparticles, or liposomes may provide the means to overcome several of these factors. By limiting the drug volume of distribution, the carrier can reduce toxicity to normal tissues, permitting higher doses and thereby overcoming functional resistance (Drummond et al., 1999) . In addition, carriers may extravasate through the flawed tumor microvasculature, increasing drug deposition and antitumor effects (Sharma et al., 1997; Zhou et al., 2002; Arnold et al., 2005) .
Paclitaxel is a clinically important cytostatic/cytotoxic agent that also exerts potent antiangiogenic effects (Belotti et al., 1996; Wang et al., 2003) . Inhibition of proliferation and migration of vascular endothelial cells, as well as alterations in microtubule dynamics, have been observed at paclitaxel concentrations 10-100 fold lower than those inducing mitotic arrest in non-endothelial cells (Belotti et al., 1996; Pasquier et al., 2005) . Additional pharmacological effects have been observed with ultra-low doses or protracted exposure (Bocci et al., 2002; Wang et al., 2003; Ling et al., 2004) . However, the activity of paclitaxel against brain tumors has been disappointing (Postma et al., 2000; Chang et al., 2001) ; they are frequently drug resistant, and paclitaxel is transported poorly across the blood-brain barrier.
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Paclitaxel aqueous solubility is poor, and the clinical product Taxol ® consists of
Cremophor-EL and ethanol (Cre-pac), which transforms spontaneously into a microemulsion (ten Tije et al., 2003) when prepared for administration. This vehicle is associated with severe, life-threatening hypersensitivity reactions (Weiss et al., 1990 ) and may interfere with taxane pharmacokinetics (PK) and antitumor activity (ten Tije et al., 2003) .
Alternative formulations have been developed that permit rapid administration and possess altered pharmacodynamic properties compared to Cre-pac. ABI-007 (Abraxane   ®   ) is an approved nanoparticulate formulation of paclitaxel complexed noncovalently with aggregated human albumin (A-pac). In animal and human trials, A-pac shows reduced toxicity compared to Cre-pac (Ibrahim et al., 2002; Desai et al., 2006) , and Phase III clinical data suggests that dose escalation is well tolerated and increases therapeutic responses (Gradishar et al., 2005) . Interestingly, A-pac produces considerably higher levels of free drug in blood than does Cre-pac, and this observation
has not yet been rationalized in terms of the reduced toxicity observed (Gardner et al., 2008) .
Microparticulate liposome-based paclitaxel formulations (L-pac) also have been developed (Riondel et al., 1992; Sharma et al., 1993) . They show activity in highly paclitaxel-resistant tumor models (Sharma et al., 1993) , and are less toxic than Cre-pac in clinical trial (Fetterly et al., 2008) . Despite their very different physicochemical characteristics, the particulate A-pac and L-pac formulations permit clinical dose escalation.
A third particulate paclitaxel formulation, consisting of a tocopherol nanoemulsion (T-pac), also has progressed from promising animal studies to clinical trial (Constantinides et al., 2006; Bulitta et al., 2009a; Bulitta et al., 2009b) . However, T-pac failed to meet its clinical objective of non-inferiority of response rates compared to Cre-pac in a Phase III pivotal trial in women with metastatic breast cancer (Bulitta et al., 2009b) . A detailed pharmacodynamic study of
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-7 -neutropenia showed deeper nadir neutrophil counts with T-pac compared to Cre-pac, and the investigators concluded that relative exposure to unbound paclitaxel at the site of toxicity was twice as large for T-pac compared to Cre-pac (Bulitta et al., 2009b) .
These disparate effects of formulation upon paclitaxel efficacy suggest the need for greater understanding of carrier-mediated effects upon taxane pharmacodynamics (PD). Here we investigated L-pac and Cre-pac pharmacodynamics in a multidrug-resistant orthotopic brain tumor model. Body weight and neutropenia were used as toxicity markers. Increase in lifespan (ILS) and tumor volume progression, quantified by magnetic resonance (MR) imaging, were used as endpoints for therapeutic efficacy. Robust, semi-mechanistic, quantitative systems pharmacological models (Lobo and Balthasar, 2002; Simeoni et al., 2004; Yang et al., 2009) were developed to evaluate mechanistic hypotheses, based on the data and the literature, that might provide insight into the differential therapeutic responses observed.
Methods
Crystalline paclitaxel was obtained from the National Cancer Institute (Bethesda, MD),
Cremophor-EL (polyethoxylated castor oil) was from BASF (Parsippany, NJ), L-α-phosphatidylglycerol (PG) was from Avanti Polar Lipids (Birmingham, AL) and L-α-phosphatidylcholine (PC) was from Genzyme (Cambridge, MA). Male Fisher 344 rats (160-200 gm) were from Harlan (Indianapolis, IN). The 9L rat gliosarcoma cell line (9L-72) was obtained from Dr. D. Deen (University of California/San Francisco) and maintained in RPMI 1640 containing 10% fetal bovine serum.
Stereotaxic tumor implantation.
Intracranial tumors were established in the caudate/putamen as described previously (Zhou et al., 2002; Arnold et al., 2005) . A suspension
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-8 -of 4x10 4 9L tumor cells in 4 µL was injected stereotaxically 4.5 mm below the exposed dura at 1.5 mm anterior-and 2.4 mm lateral to Bregma.
Paclitaxel Formulations. In order to administer Cre-pac at the necessary doses, a stock solution was prepared at a higher concentration than in Taxol   ® . Crystalline drug was dissolved in ethanol at 30 mg/ml and diluted with an equal volume of Cremophor EL. Immediately before administration, it was diluted 5-fold with sterile saline to a final concentration of 3 mg/ml.
Paclitaxel was formulated in PC:PG (9:1 mol:mol) liposomes at a drug:lipid ratio of 3 mol% as described (Sharma and Straubinger, 1994) . Briefly, the drug/lipid mixture in chloroform was dried, resuspended in t-butanol at a phospholipid concentration of 150 mM, shell-frozen in liquid nitrogen, and lyophilized for 24h. The resulting powder was hydrated at room temperature with saline and extruded sequentially through dual stacked polycarbonate membranes of 2.0, 0.4, 0.1 and 0.08 μm, with three passes through each pore size. The particle size resulting from this extrusion procedure would be approx. 110 nm +/-25% (Mayer et al., 1986) . Association of drug with liposomes was greater than 90% (Sharma and Straubinger, 1994) . The final paclitaxel concentration was 3-4 mg/ml and the lipid concentration was 100-130 mM. The physical stability of L-pac and absence of precipitated material was verified by microscopy (Sharma and Straubinger, 1994 
The change in ANC during treatment was calculated as
where ANC 1 is the ANC during treatment, and ANC 0 is the pretreatment value.
Lifespan. Animals were monitored for signs of drug toxicity, such as diarrhea (gastrointestinal tract damage), increased intracranial pressure due to tumor growth (seizures, paralysis in contra-lateral limbs), or pigmentation around the eyes, mouth and nose. Death ensues within 24 h of these signs, and therefore moribund animals were euthanized. The death was recorded as occurring on the following day. Statistical significance of changes in the median lifespan (MLS) of treatment groups was evaluated using the non-parametric Mann-Whitney test.
A two-tailed student t-test was used to compare tumor volumes of treatment and control groups.
Tumor volume estimation. Rats were anesthetized with ketamine/xylazine (66.7/6.7 mg/kg) i.m. and the head was immobilized in a nonferrous stereotaxic frame. T 2 -weighted proton spin echo images (TR/TE=2000/120 ms) were acquired on a 1.5 T whole body scanner (Signa Endoplus, General Electric, Milwaukee, WI) interfaced to a custom transceiver coil tuned at 63.87 MHz. The voxel size was 0.31x0.31x1 mm 3 . Tumor volume was calculated from image data as described previously (Zhou et al., 2002) .
This article has not been copyedited and formatted. The final version may differ from this version. Pharmacodynamic theory and analysis. Two semi-mechanistic systems pharmacology models of drug-mediated tumor cell growth inhibition (Lobo and Balthasar, 2002; Simeoni et al., 2004) were employed to investigate formulation-and schedule-dependent differences in paclitaxel efficacy. A key feature common to these models is the mathematical accommodation of the protracted delay between treatment and observable effects upon tumor volume. Model A (Fig. 1A) hypothesizes a signal transduction cascade interposed between drug/receptor interaction and tumor growth delay (Lobo and Balthasar, 2002) , whereas Model B (Fig. 1B) hypothesizes immediate drug effects upon the tumor that elicit a temporally protracted process of cell death (Simeoni et al., 2004) . Despite the apparent similarity of these transit compartment models, they are non-interchangeable in terms of their behavior with different types of cancer drug response data (Yang et al., 2009) . Additional refinements of Model B were explored; Model C ( Fig. 1C) incorporates the concept that treatment induces an additional, temporally transient tumor component that is neither dividing nor committed to cell death. This fraction could correspond to drug treatment effects such as edema or creation of a population of quiescent cells.
A 4 th preliminary model (S1; not shown) explored the concept that treatment transiently increases tumor susceptibility to drug, either through increased vascular permeability or increased intratumor drug diffusion (Jang et al., 2001; Lu et al., 2007) . This concept alone did not improve capture of the experimental data beyond that achieved with the other hypothesized mechanisms.
Model D (Fig. 1D ) represents a hybrid of Models A and B, and includes the concept of transiently enhanced drug sensitivity from Model S1.
Optimal parameter estimates were calculated for each model. Quantifiable metrics such as sum-of-squared-error (SSE) and Akaike's information criterion (AIC) were used to weigh the impact of each conceptual component upon the fidelity with which the model captured the This article has not been copyedited and formatted. The final version may differ from this version. Several expedients were used to simplify implementation of key conceptual points so that the models did not become over-parameterized with assumptions that were not experimentally justifiable.
Model D (Fig. 1D ) is driven by the pharmacokinetic driving function A(t) (amount of paclitaxel in the central compartment at time t), which was derived from published data for Crepac and L-pac in rats (Fetterly and Straubinger, 2003) . As shown in Eq. 1, the initiating signal, driven by the drug amount in plasma, is nonlinear and characterized by the Hill function parameters E max (maximal effect) and A 50 (amount of drug producing 50% of E max ). This assumption is defensible pharmacologically, given the numerous cases in which the Hill function accurately describes drug concentration-response data based on receptor occupancy, and was also found to be necessary to account for the greater efficacy observed for lower doses administered more frequent (Results).
In Eq. 2, the signal initiated by exposure to drug is implemented as a signaling transit compartment (s) (Mager and Jusko, 2001) (Fig. 1D) , and includes the concept explored in Model S1 that treatment transiently increases tumor susceptibility to drug (Jang et al., 2001; Lu et al., 2007) . This signal might reflect increased cellular drug uptake/accumulation, tumor decompression resulting from paclitaxel-induced apoptosis, or other mathematically-equivalent, This article has not been copyedited and formatted. The final version may differ from this version. The tumor volume w(t) is composed of cells in proliferating (x 1 ) and quiescent states (x 2 ) (Eq. 3). These states are characterized by Eq. 4 and Eq. 5. state (x 2 ) is a saturable function of the drug-induced signal (s). The parameter k 2 is a secondorder cell-kill constant representing the maximum effect, and the s 50 term represents the signal level producing half-maximal effect. This functionality also serves to increase the efficacy of lower dose/higher frequency schedules, which was observed experimentally.
The model structure could not account for formulation-dependent differences in efficacy.
To do so, it was necessary to estimate E max and s 50 independently for the two formulations, which improved capture of the data by the model predictions. For this reason, they are designated E * max and s * 50 in Eq. 1 and Eq. 6. The value of ψ , the transition term for tumor growth rate, was fixed to 20 per the original publication (Simeoni et al., 2004) . The remaining parameters were regressed simultaneously in MATLAB (v.7, Mathworks, Natick, MA). For parameter estimation purposes, a weighted minimization of the residual sum of the squared error was used.
Results
The MTD (maximum tolerated dose) of both paclitaxel formulations was investigated to establish doses and treatment schedules for therapeutic experiments. A single i.v. dose of 85 mg/kg paclitaxel was reported was lethal to 20-40% of Sprague Dawley rats (Kadota et al., 1994) . Incorporation of paclitaxel in liposomes increases the MTD of paclitaxel (Sharma et al., 1993) , and so the above-reported dose was tested in rats bearing 14-day intracranial 9L tumors, as were doses that were approx. 20% higher and lower. Severe GI tract effects or weight loss were observed for both formulations at ≥ 85 mg/kg (not shown). Onset of these symptoms was delayed approx. 24 h in animals treated with L-pac. From these studies, 50 mg/kg was chosen as the maximum single-administration dose. Two additional dosing regimens were selected: 80 mg/kg given as two injections of 40 mg/kg separated by 7 days, and 60 mg/kg, given as three injections of 20 mg/kg over 7 days (i.e. 3-4 days apart).
This article has not been copyedited and formatted. The final version may differ from this version. Therapeutic experiments were initiated on day 8 (d8) after tumor implantation. Body weight was monitored as a PD marker of overall toxicity (Fig. 2) and to verify that each dosing regimen approximated the MTD for that treatment protocol. Tumor-bearing control rats experienced a 10% weight gain. Body weight peaked approx. 19d after tumor implantation, at which time the animals became symptomatic from tumor growth and succumbed quickly. In groups treated with Cre-pac ( Fig. 2A) , a single dose of 50 mg/kg on d8 resulted in approx. 10%
weight loss, which recovered within a week. L-pac at 50 mg/kg also mediated weight loss (Fig.   2B ), but with a shallower nadir. The amount of phospholipid administered was approx. 39 μmol, which could result in mild, reversible blockade of the reticuloendothelial system, but should not exert toxicity.
Cre-pac, given as 40 mg/kg on d8 and d15 (80 mg/kg cumulative), resulted in 8% weight loss after the first injection, which recovered partially. However, weight loss was precipitous after the 2 nd treatment and did not recover. L-pac given at the same dose and schedule resulted in a similar pattern of weight loss but was less severe, and the nadir after dosing was shallower. The phospholipid dose was approx. 21 μmol, and would not be expected to contribute to toxicity.
The lowest cumulative dose of Cre-pac (60 mg/kg given in 7 days as 20 mg/kg doses on d8, d11, and d15) was more toxic than the 80 mg/kg cumulative dose schedule, also given in 7 days (40 mg/kg doses on d8 and d15). Body weight declined with each administration and fell precipitously following the 3 rd injection. In striking contrast, animals treated with the equivalent regimen of L-pac continued to gain weight following the first dose. Weight declined after the 2 nd and 3 rd doses, but increased after the regimen was completed. Each phospholipid dose was approx. 21 μmol, and would not be expected to contribute to toxicity.
This article has not been copyedited and formatted. The final version may differ from this version. Bone marrow suppression was also evaluated to compare formulation toxicity. For animals receiving Cre-pac as 40 mg/kg x2, neutrophil counts returned to baseline in the 7 days between treatments (Fig. 2C) . Neutropenia was more sustained with L-pac at this dose level, and counts did not return to baseline before the second dose was given (Fig. 2D) .
Progressive neutropenia was observed in animals receiving either formulation in the 20 mg/kg x3 dose regimen. Following the 2 nd dose, neutrophil counts fell to 10% of the pretreatment value, a level regarded clinically as severe neutropenia. By d23 after tumor implantation (8 days after the 3 rd dose), animals treated with Cre-pac succumbed. Notably, that represents the median survival time for untreated tumor-bearing controls (below). Therefore, ineffective control of tumor progression could not be discounted as a cause of death. In striking contrast, animals treated with 20 mg/kg x3 L-pac recovered to baseline neutrophil counts 9 days after the 3 rd dose (Fig. 2D ).
Increase in median lifespan was examined as measure of overall therapeutic efficacy ( Fig.   3 ) and for statistical comparison of the two formulations (Table 1) . L-pac given as 20 mg/kg x3 conferred the greatest ILS (40%, p<0.0001). A higher cumulative L-pac dose (40 mg/kg x2) mediated a significant but lesser ILS (27%, p<0.005). A single dose of 50 mg/kg L-pac did not alter lifespan significantly (Table 1) .
In contrast, no dose or schedule of Cre-pac conferred a survival advantage relative to vehicle-treated controls. The 20 mg/kg x3 dosing regimen, which yielded the greatest ILS as Lpac, was the most toxic as Cre-pac. Lifespan was reduced approx 10%, but this trend was not statistically significant (p=0.15). volume progression was monitored repetitively during treatment (Fig. 5A, B ).
The rate of tumor expansion was reduced significantly for animals treated with L-pac ( Fig.   5B ). As early as d13, tumors in animals treated with 20 x3 mg/kg L-pac were significantly smaller than controls (p<0.002), and on d23, the last day on which volumes could be compared with controls, animals treated with 20 mg/kg x3 and 40 mg/kg x2 L-pac had smaller tumors (p<0.0001 and p<0.002, respectively). Consistent with the ILS data, the greatest reduction in tumor volume progression was observed in animals treated with L-pac at a lower cumulative dose but higher frequency (20 mg/kg x3). The highest L-pac dose (50 mg/kg x1) was ineffective.
For animals treated with Cre-pac, significant tumor growth retardation was observed only in animals treated with 20 mg/kg x3 ( Fig. 5A ; p<0.002 on d21). However, 100% of those animals succumbed by d23, which coincided with the median day of death for control animals.
The 40 mg/kg x2 Cre-pac regimen was ineffective.
Two mechanistically distinct types of pharmacological system models were employed to analyze the observed formulation-and regimen-dependent therapeutic effects quantitatively.
Neither base model A nor B (Lobo and Balthasar, 2002; Simeoni et al., 2004) fit the data well, based on objective criteria (Table 2 ) and visual inspection. Model D (Fig. 1) from the two base models; it hypothesizes that a signal transduction process conveys a 'kill signal' that is related in magnitude to the drug pharmacokinetic profile, and that the effect of this signal is to shunt a proportion of tumor cells to a commitment to cell death. It also incorporates the concept of schedule-dependent tumor 'priming' (Lu et al., 2007) that was tested in Model S1
(Methods).
Objective criteria such as SSE and AIC values supported the selection of Model D as the final system model ( Table 2 ). When fit simultaneously to all data, it best captured the time course of tumor volume progression for control-and treated animals ( Fig. 5A, B) . Table 3 shows the estimated model parameters.
Model D represents the tumor priming effect as a driving state (s), shown in Fig. 5C and 5D. Treatment transiently increased the magnitude of the driving state, and repetitive treatments of the appropriate frequency were observed to cause s to accumulate or increase in magnitude.
This model feature was required to accommodate the greater observed efficacy of the higher frequency/lower dose schedules, which was confirmed by statistical analysis (Table 1) and is supported by empirical data from the literature (Jang et al., 2001; Lu et al., 2007) .
Although the structure of Model D could account for schedule-dependent differences in efficacy, it could not account for the formulation-dependent differences observed with identical doses/schedules. Formulation-specific effects were explored within the models, and capture of the data was improved by fitting specific parameters independently. It was found that the model predictions were best able to capture the higher efficacy of L-pac by fitting the E max (the initiating signal capacity) independently for the two formulations. Fig. 5C and 5D show the mechanistic predictions of the model: for the same dose level and schedule of administration, the susceptibility factor (driving force s) accumulates to higher levels for L-pac. This is a direct This article has not been copyedited and formatted. The final version may differ from this version. result of the fact that the estimated value of the E max term is 3.5-fold higher for L-pac than for
Cre-pac (0.794 vs. 0.227), and this higher driving force serves to magnify L-pac PD effects.
Interpreted literally, increased L-pac efficacy cannot be explained simply by the elevation of dose that is feasible because of reduced toxicity; rather, a higher maximal efficacy of L-pac must be invoked as well.
Time-to-progression also was examined. A volume of 400±20 mm 3 represented a threshold of morbidity, in that death generally ensued within 48 h. As shown in Table 1 , growth delay appeared to be consistent with the observed change in median life span for all treatment groups except for the group treated with 20 mg/kg x3 Cre-pac; MR imaging showed tumor growth delay for that regimen, but lifespan was not extended.
Discussion
The persistently poor prognosis of brain tumors drives the search for new therapeutic approaches. A growing realization from clinical trials is that 'repackaging' clinically effective drugs in more efficacious carrier-based formulations (Sparreboom et al., 2005a) penetration compared to Cre-pac (Sparreboom et al., 2005b; Desai et al., 2006) . The enhanced biodistribution of A-pac may arise from transport of the carrier via the gp60 endothelial cell receptor for albumin and interactions with the albumin-binding SPARC (secreted protein acid rich in cysteine) (Nyman et al., 2005; Desai et al., 2006) . The drug release rate from the albumin nanoparticle is unknown. The L-pac formulation has a larger central volume of distribution compared to Cre-pac, but much slower distributional clearance (Fetterly et al., 2001) . Based on the data, L-pac is more effective than Cre-pac at confining the drug to the circulating reservoir, which restricts the exposure of critical normal tissues. The rate of drug release from L-pac also is unknown, but based on PK analysis, appears to be fairly rapid (Fetterly and Straubinger, 2003) .
Finally, the tocopherol-based T-pac nanoemulsion has a volume of distribution intermediate between L-pac and Cre-pac, and the release rate of drug from the circulating carrier to the plasma was estimated to be lower than from Cre-pac (Bulitta et al., 2009a) .
The paradox presented by these formulations is that two are very different in physicochemical properties but similar pharmacodynamically: A-pac and L-pac both possess markedly lower toxicity in animal (Riondel et al., 1992; Sharma et al., 1993; Sharma and Straubinger, 1994; Desai et al., 2006) and human studies (Gradishar et al., 2005; Fetterly et al., 2008) . In contrast, the T-pac formulation, which is compositionally more similar to L-pac, appears to be more toxic than Cre-pac clinically (Bulitta et al., 2009b) . Thus while the observed improvement in paclitaxel efficacy by incorporation into particulate carriers represents an important clinical advance, the physicochemical basis of this beneficial effect is unclear.
In the present study, Cre-pac and L-pac were compared in terms of toxicity and antitumor L-pac administered at a higher cumulative dose (80 mg/kg), but with longer between-dose intervals (7 days) mediated a significant increase in median life span (29%; p<0.0002). However, this regimen was inferior to the lower cumulative dose (60 mg/kg) given as smaller, more frequent doses.
Neutropenia was similar for the Cre-pac and L-pac, but appeared to be more sustained with L-pac at the lower dose/higher frequency. Nonetheless, neutrophil counts returned to baseline values following cessation of treatment with L-pac, and the animals survived. In contrast, animals treated with Cre-pac did not survive. Recent clinical trials comparing a similar L-pac formulation to Cre-pac at more conservative dose intensities showed that neutropenia was milder for L-pac (Fetterly et al., 2008) .
Body weight change clearly discriminated between formulations. Cre-pac caused a substantial reduction in body weight, and toxicity was severe with some dosing regimens. L-pac was better tolerated, and for some schedules, it would be feasible to administer higher dose intensities.
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The superior tumor growth delay observed for L-pac may arise from a number of mechanisms. Liposomal incorporation retards drug distribution to the peripheral tissues, and may increase deposition in tumors. Although liposomes do not cross an intact blood-brain barrier, they can extravasate through defects in the tumor vasculature (Sharma et al., 1997; Arnold et al., 2005) . For the L-pac formulation used here, our PK model estimated that drug release rates are rapid but delayed compared to Cre-pac. The PK of total paclitaxel in blood is similar for L-pac and Cre-pac (Fetterly and Straubinger, 2003) . Understanding the role of the drug release rate in efficacy vs. toxicity is not only elusive but perhaps key in understanding the differential toxicity and efficacy of these alternative formulations (Gardner et al., 2008) . Because of the relatively rapid clearance of the type of liposomes used here, tumor drug deposition may be lower than achieved with long-circulating liposome formulations in this model (Arnold et al., 2005) .
Nonetheless, some enhancement of drug deposition in hyperpermeable regions of the tumor might occur with L-pac, particularly given the previous observations that paclitaxel at appropriately-spaced intervals can increase deposition of drug or drug-loaded nanoparticles (Jang et al., 2001; Lu et al., 2007) . Observations of paclitaxel pharmacological activity at ultra-low concentrations and protracted exposure times (Bocci et al., 2002; Wang et al., 2003; Ling et al., 2004) suggest that persistent low concentrations of paclitaxel in the blood, or a small intra-tumor depot of paclitaxel, could exert sustained pharmacodynamic effects.
Repetitive, non-invasive MR imaging enabled the disentanglement of ineffective tumor growth control vs. life-shortening toxicity, and enabled the application of semi-mechanistic, quantitative pharmacodynamic analysis to explore hypotheses underlying the pharmacological differences between the formulations. Five model structures, derived from two distinct types of transit compartment models (Sun and Jusko, 1998; Mager and Jusko, 2001) , were evaluated This article has not been copyedited and formatted. The final version may differ from this version. quantitatively for their ability to capture formulation-and treatment-dependent effects on tumor volume progression. One model type (Fig. 1A) represents the effect of drug as initiating a cellular signal transduction process that ultimately impinges upon a 'cell kill' mechanism (Lobo and Balthasar, 2002) , whereas the second (Fig. 1B) represents the effect of drug as shunting a proportion of dividing cells of the tumor mass into a commitment to cell death (Simeoni et al., 2004) . Both mechanisms have been observed for oncology drugs.
Although neither base model fit the data well, they represented the starting point for development of a novel hybrid model (Model D, Fig. 1 ) that provided excellent fits to the data.
Conceptually, a signal transduction process is initiated in this model by the administration of drug, and cell death is non-instantaneous. Both features resemble reported taxane mechanisms of action (Blagosklonny and Fojo, 1999; Ling et al., 2004) . The addition of a hypothesized mechanism of transient tumor 'priming' effect of closely spaced doses (Jang et al., 2001; Lu et al., 2007) provided the best simultaneous fitting of all data. It is as yet unsettled as to whether this priming effect arises from effects upon tumor vasculature, tumor cells, or both. Nonetheless, it was observed that each of these mechanistic assumptions was necessary to explain the observation that a lower cumulative dose, given in smaller, more frequent administrations, was more effective than larger doses administered less frequently. Interestingly, the tumor priming effect was only observed with L-pac in this advanced, drug-resistant tumor model because therapeutically effective doses could not be achieved with Cre-pac.
The structure of Model D could not account for the greater activity of L-pac over Cre-pac when both were given at identical doses and schedules. Fitting of the E max model parameter independently for the two formulations produced the best objective capture of the data. At face value, this finding suggests that although both formulations are similar in potency, the liposomal
-23 -formulation possesses a greater maximal effect and a more persistent tumor priming signal.
Regardless of the literal interpretation of these model components, the requirement to estimate them in a formulation-dependent manner suggests that reduction in dose-limiting toxicity may not be the only mechanism underlying the superiority of L-pac over Cre-pac in therapeutic efficacy.
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